망막약 시장(2026-2030년)

The global retinal drugs market is forecasted to grow by USD 10016.8 mn during 2025-2030, accelerating at a CAGR of 7.1% during the forecast period. The report on the global retinal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing adoption of biosimilars and cost effective alternatives, integration of digital health and teleophthalmology platforms, strategic emphasis on patient centric care and journey optimization.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global retinal drugs market is segmented as below:

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By Indication

• Macular degeneration
• Diabetic eye disease
• Others

By Drug Class

• VEGF-A antagonist
• TNF-A inhibitor

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the standardization of performance based visual assessments as one of the prime reasons driving the global retinal drugs market growth during the next few years. Also, decentralization of clinical trial operations and ai driven optimization of trial feasibility and recruitment will lead to sizable demand in the market.

The report on the global retinal drugs market covers the following areas:

• Global retinal drugs market sizing
• Global retinal drugs market forecast
• Global retinal drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global retinal drugs market vendors that include AbbVie Inc., Amgen Inc., ANI Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Astellas Pharma Inc., Bausch Lomb Corp., Bayer AG, Biogen Inc., Celltrion Co. Ltd., Coherus Oncology Inc, F. Hoffmann La Roche Ltd., Lupin Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Samsung Electronics Co. Ltd., Sandoz Group AG, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global retinal drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Retinal Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Retinal Drugs Market 2020 - 2024 ($ million)
• 5.2 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.3 Indication segment analysis 2020 - 2024
  • Historic Market Size - Indication Segment 2020 - 2024 ($ million)
• 5.4 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global retinal drugs market
• 6.2 Impact of geopolitical conflicts on global retinal drugs market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Distribution Channel

• 8.1 Market segments
• 8.2 Comparison by Distribution Channel
• 8.3 Hospital pharmacy - Market size and forecast 2025-2030
• 8.4 Retail pharmacy - Market size and forecast 2025-2030
• 8.5 Online pharmacy - Market size and forecast 2025-2030
• 8.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Indication

• 9.1 Market segments
• 9.2 Comparison by Indication
• 9.3 Macular degeneration - Market size and forecast 2025-2030
• 9.4 Diabetic eye disease - Market size and forecast 2025-2030
• 9.5 Others - Market size and forecast 2025-2030
• 9.6 Market opportunity by Indication
  • Market opportunity by Indication ($ million)

10 Market Segmentation by Drug Class

• 10.1 Market segments
• 10.2 Comparison by Drug Class
• 10.3 VEGF-A antagonist - Market size and forecast 2025-2030
• 10.4 TNF-A inhibitor - Market size and forecast 2025-2030
• 10.5 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Singapore - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 South Africa - Market size and forecast 2025-2030
  • 12.6.4 Argentina - Market size and forecast 2025-2030
  • 12.6.5 UAE - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
  • 12.6.7 Egypt - Market size and forecast 2025-2030
  • 12.6.8 Chile - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Growing adoption of biosimilars and cost effective alternatives
  • Integration of digital health and teleophthalmology platforms
  • Strategic emphasis on patient centric care and journey optimization
• 13.2 Market challenges
  • Complex reimbursement and financial pressures
  • Supply chain complexity and logistics vulnerability
  • Regulatory burdens and clinical trial design constraints
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Standardization of performance based visual assessments
  • Decentralization of clinical trial operations
  • AI driven optimization of trial feasibility and recruitment

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key offerings
  • SWOT
• 15.6 ANI Pharmaceuticals Inc.
  • ANI Pharmaceuticals Inc. - Overview
  • ANI Pharmaceuticals Inc. - Product / Service
  • ANI Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.7 Apellis Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc. - Overview
  • Apellis Pharmaceuticals Inc. - Product / Service
  • Apellis Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.8 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 15.9 Bausch Lomb Corp.
  • Bausch Lomb Corp. - Overview
  • Bausch Lomb Corp. - Business segments
  • Bausch Lomb Corp. - Key offerings
  • Bausch Lomb Corp. - Segment focus
  • SWOT
• 15.10 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.11 Biogen Inc.
  • Biogen Inc. - Overview
  • Biogen Inc. - Product / Service
  • Biogen Inc. - Key offerings
  • SWOT
• 15.12 Celltrion Co. Ltd.
  • Celltrion Co. Ltd. - Overview
  • Celltrion Co. Ltd. - Product / Service
  • Celltrion Co. Ltd. - Key offerings
  • SWOT
• 15.13 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.14 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.16 Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc. - Overview
  • Regeneron Pharmaceuticals Inc. - Product / Service
  • Regeneron Pharmaceuticals Inc. - Key news
  • Regeneron Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.17 Samsung Electronics Co. Ltd.
  • Samsung Electronics Co. Ltd. - Overview
  • Samsung Electronics Co. Ltd. - Business segments
  • Samsung Electronics Co. Ltd. - Key news
  • Samsung Electronics Co. Ltd. - Key offerings
  • Samsung Electronics Co. Ltd. - Segment focus
  • SWOT
• 15.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations